false
0000313143
0000313143
2024-05-21
2024-05-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 21, 2024
HAEMONETICS CORPORATION
(Exact name of registrant as specified
in its charter)
Commission File Number: 001-14041
Massachusetts |
|
04-2882273 |
(State or other jurisdiction
of incorporation) |
|
(IRS Employer
Identification No.) |
|
125 Summer Street
Boston, MA 02110 |
(Address of principal executive offices, including zip code) |
781-848-7100
(Registrant’s telephone number,
including area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, $.01 par value per share |
|
HAE |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 |
Regulation FD Disclosure. |
On May 21, 2024, Haemonetics Corporation issued a press release
announcing its intention to offer $525 million aggregate principal amount of convertible senior notes due 2029 in a private offering
pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1
and incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HAEMONETICS CORPORATION |
|
|
|
Date: May 21, 2024 |
By: |
/s/ James C. D’Arecca |
|
Name: |
James C. D’Arecca |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
Investor Contacts: |
|
Olga Guyette, Sr. Director-Investor Relations & Treasury |
David Trenk, Manager-Investor Relations |
(781) 356-9763 |
(203) 733-4987 |
olga.guyette@haemonetics.com |
david.trenk@haemonetics.com |
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com
Haemonetics Announces Proposed Convertible
Senior Notes Offering
BOSTON, MA, May 21, 2024 -- Haemonetics Corporation (“Haemonetics”)
(NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of
Convertible Senior Notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional
buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Haemonetics also expects
to grant the initial purchasers of the notes an option to purchase up to an additional $75,000,000 aggregate principal amount of the notes.
The notes will be senior, unsecured obligations of Haemonetics,
will accrue interest payable semi-annually in arrears, and will mature on June 1, 2029, unless earlier repurchased, redeemed or
converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Haemonetics
will settle any conversion amounts of the notes up to the $1,000 principal amount of the notes in cash, and any conversion amounts
in excess of the principal amount in cash, shares of Haemonetics’ common stock or a combination thereof, at
Haemonetics’ election. The final terms of the notes, including the initial conversion price, interest rate and certain other
terms of the notes, will be determined at the time of pricing.
Haemonetics intends to use the net proceeds from the offering to fund
the cost of entering into the capped call transactions described below and to use the remainder of the proceeds for working capital and
other general corporate purposes, which may include the repayment and/or repurchase of indebtedness. If the initial purchasers exercise
their option to purchase additional notes, then Haemonetics intends to use a portion of the additional net proceeds to fund the cost of
entering into additional capped call transactions as described below and the remainder for working capital and other general corporate
purposes.
In connection with the pricing of the notes, Haemonetics expects to
enter into privately negotiated capped call transactions with certain financial institutions (the “option counterparties”).
The capped call transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to
the notes, the number of shares of Haemonetics’ common stock initially underlying the notes. If the initial purchasers exercise
their option to purchase additional notes, Haemonetics expects to enter into additional capped call transactions with the option counterparties.
The capped call transactions are expected generally to reduce or offset the potential dilution to Haemonetics’ common stock upon
any conversion of the notes and/or to offset any potential cash payments Haemonetics is required to make in excess of the principal amount
of the converted notes, as the case may be, with such reduction and/or offset subject to a cap.
Haemonetics expects that, in connection with establishing their initial
hedges of the capped call transactions, the option counterparties or their respective affiliates will enter into various derivative transactions
with respect to Haemonetics’ common stock and/or purchase shares of Haemonetics’ common stock concurrently with or shortly
after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Haemonetics’
common stock or the notes at that time.
In addition, Haemonetics expects the option counterparties or
their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to
Haemonetics’ common stock and/or purchasing or selling Haemonetics’ common stock or other securities of Haemonetics in
secondary market transactions following the pricing of the notes and from time to time prior to the maturity of the notes (and are
likely to do so following any conversion of the notes, any repurchase of the notes by us on any fundamental change repurchase date,
any redemption date or any other date on which the notes are retired by Haemonetics, in each case if Haemonetics exercises its
option to terminate the relevant portion of the capped call transactions, where such termination is at its option).This activity
could also cause or avoid an increase or a decrease in the market price of Haemonetics’ common stock or the notes, which could
affect a noteholder’s ability to convert the notes, and, to the extent the activity occurs during any observation period
related to a conversion of the notes, it could affect the number of shares, if any, and value of the consideration that noteholders
will receive upon conversion of the notes.
The notes will be sold only to persons reasonably believed to be
qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of
common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities
laws, and unless so registered, the notes and any such shares cannot be offered or sold except pursuant to an applicable exemption from,
or in a transaction not subject to, such registration requirements. This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any offer or sale
of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to
providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of
healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital
transfusion services.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements, including,
among other things, statements regarding the completion, timing and size of the proposed offering, the terms of the notes and the capped
call transactions, the expected use of proceeds, expectations regarding actions of the option counterparties and their respective affiliates, and repurchase transactions.
In addition, other written or oral statements that constitute forward-looking statements may be made by Haemonetics or on its behalf.
Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,”
“should,” “estimate,” “may,” “target,” “project,” or variations of such words
and similar expressions are intended to identify such forward-looking statements. Forward-looking statements represent the current expectations
of Haemonetics regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to
differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are (i) the risk that
the offering will not be consummated, (ii) changes as a result of market conditions, including market interest rates, (iii) fluctuations
in the trading price and volatility of Haemonetics’ common stock, (iv) the risk that the capped call transactions will not
become effective, (v) whether and on what terms Haemonetics may repay and/or repurchase indebtedness, (vi) unanticipated uses
of capital, (vii) the impact of general economic, industry or political conditions in the United States or internationally, and (viii) risks
relating to Haemonetics’ business, including those described in Haemonetics’ Annual Report on Form 10-K for the year
ended March 30, 2024 and other filings with the U.S. Securities and Exchange Commission. The forward-looking statements included
in this press release speak only as of the date of this press release, and Haemonetics does not undertake to update the statements included
in this press release for subsequent developments, except as may be required by law.
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Haemonetics (NYSE:HAE)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Haemonetics (NYSE:HAE)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024